Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies

ABSTRACT Immunogenicity evaluations in human papillomavirus (HPV) vaccine trials have relied on serological samples, yet cervical antibodies are likely to be most relevant for protection against infection. In order to assess functional antibody levels at the cervix, the secreted-alkaline-phosphatase neutralization assay (SEAPNA) was used to measure HPV-neutralizing activity. We assessed the variability of the SEAPNA with serum samples after vaccination with an HPV type 16 (HPV16) L1 virus-like particle vaccine and whether the SEAPNA can be used to monitor neutralizing activity at the cervix. The SEAPNA has an overall coefficient of variation of 29.3%. Recovery from ophthalmic sponges was assessed by spiking V5 (mouse anti-HPV16) antibody onto and extracting it from sterile Merocel and Ultracell sponges and sponges used to collect specimens from participants. V5 recovery from sterile Merocel sponges was complete, yet that from Ultracell sponges was null. The mean V5 recoveries from participant Ultracell and Merocel sponges were 61.2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix.

[1]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[2]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[3]  K. Anastos,et al.  Serological Detection of Human Papillomavirus Type 16 Infection in Human Immunodeficiency Virus (HIV)-Positive and High-Risk HIV-Negative Women , 2006, Clinical and Vaccine Immunology.

[4]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[5]  K. Jansen,et al.  Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 , 2005, Clinical Diagnostic Laboratory Immunology.

[6]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[7]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[8]  S. Franceschi,et al.  Prevalence of human papillomavirus infection in women in Turin, Italy. , 2005, European journal of cancer.

[9]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[10]  M. Schiff,et al.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.

[11]  D. Lowy,et al.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. , 2004, Virology.

[12]  D. Lowy,et al.  Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles , 2004 .

[13]  P. Castle,et al.  Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions , 2004, Clinical Diagnostic Laboratory Immunology.

[14]  Allan Hildesheim,et al.  Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. , 2004, Revista panamericana de salud publica = Pan American journal of public health.

[15]  M. Sherman,et al.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica , 2003, British Journal of Cancer.

[16]  P. Coursaget,et al.  Prevalence of human papillomavirus infection in women in Busan, South Korea , 2003, International journal of cancer.

[17]  D. Lowy,et al.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. , 2003, Journal of the National Cancer Institute.

[18]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[19]  J. Dillner.  The serological response to papillomaviruses. , 1999, Seminars in cancer biology.

[20]  M. Schiffman,et al.  Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. , 1999, Journal of immunological methods.

[21]  J. Dillner,et al.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. , 1996, Virology.

[22]  Darren W. Henderson,et al.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins , 1994, Journal of virology.